相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liquid biopsies: Potential and challenges
Isabel Heidrich et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
Mei-Mei Zheng et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
Charu Aggarwal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies
Mauli Shah et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo et al.
CLINICAL CANCER RESEARCH (2021)
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2020)
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions
Laure Sorber et al.
MOLECULAR DIAGNOSIS & THERAPY (2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
J. H. Shim et al.
ANNALS OF ONCOLOGY (2020)
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases
Philip C. Mack et al.
CANCER (2020)
Is tissue still the issue in detecting molecular alterations in lung cancer?
Chong-Kin Liam et al.
RESPIROLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Personalized Medicine: Recent Progress in Cancer Therapy
Valentina Gambardella et al.
CANCERS (2020)
Integrating genomic features for non-invasive early lung cancer detection
Jacob J. Chabon et al.
NATURE (2020)
Liquid biopsy for early stage lung cancer moves ever closer
Christian Rolfo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Manuel Caitano Maia et al.
NATURE REVIEWS UROLOGY (2020)
Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers
Diego Fernandez-Lazaro et al.
DIAGNOSTICS (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
Christian Rolfo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
Mariantonia Nacchio et al.
JOURNAL OF THORACIC DISEASE (2020)
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Andrew J. Piper-Vallillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance
Lee S. Schwartzberg et al.
NPJ PRECISION ONCOLOGY (2020)
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
J. J. Lin et al.
ANNALS OF ONCOLOGY (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer
Sandra Ortiz-Cuaran et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
Ryan Woodhouse et al.
PLOS ONE (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy
Maria Jose Serrano et al.
CANCER DISCOVERY (2020)
Understanding EGFR heterogeneity in lung cancer
Antonio Passaro et al.
ESMO OPEN (2020)
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles
Bart Koopman et al.
JCO PRECISION ONCOLOGY (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman et al.
NATURE CANCER (2020)
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Everett J. Moding et al.
NATURE CANCER (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
B. T. Li et al.
ANNALS OF ONCOLOGY (2019)
Promises, promises, and precision medicine
Michael J. Joyner et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
Ibiayi Dagogo-Jack et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol
Laure Sorber et al.
CANCERS (2019)
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2019)
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Sergio Villatoro et al.
MOLECULAR ONCOLOGY (2019)
LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2019)
Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?
A. Russo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
PD-L1 and Other Potential Predictive Biomarkers Measured in Plasma by RT-PCR in cfRNA and cfDNA to Monitor Clinical Responses in Metastatic Lung Cancer Patients
L. Raez et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Pedram Razavi et al.
NATURE MEDICINE (2019)
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
J. Zugazagoitia et al.
ANNALS OF ONCOLOGY (2019)
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Matteo Canale et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Next-generation sequencing in liquid biopsy: cancer screening and early detection
Ming Chen et al.
HUMAN GENOMICS (2019)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
N. Guibert et al.
ANNALS OF ONCOLOGY (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen et al.
SCIENCE (2018)
Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules
Mingzhi Ye et al.
JOURNAL OF THORACIC DISEASE (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
E S Kim et al.
ANNALS OF ONCOLOGY (2018)
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Yi-Long Wu et al.
LUNG CANCER (2018)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen et al.
NATURE (2018)
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
Christian Rolfo et al.
ESMO OPEN (2018)
There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression
Eduardo Clery et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
A Comparison of Cell-Free DNA Isolation Kits Isolation and Quantification of Cell-Free DNA in Plasma
Laure Sorber et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
Biagio Ricciuti et al.
MEDICAL ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA
Akira Ooki et al.
CLINICAL CANCER RESEARCH (2017)
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Filip Janku et al.
CLINICAL CANCER RESEARCH (2017)
Development of a gene panel for nextgeneration sequencing of clinically relevant mutations in cell-free DNA from cancer patients
Umberto Malapelle et al.
BRITISH JOURNAL OF CANCER (2017)
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz et al.
CLINICAL CANCER RESEARCH (2016)
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
M. Jamal-Hanjani et al.
ANNALS OF ONCOLOGY (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
cMET Exon 14 Skipping: From the Structure to the Clinic
Nele Van der Steen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
James L. Sherwood et al.
PLOS ONE (2016)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Targeted Therapies in Non-Small Cell Lung Cance-rBeyond EGFR and ALK
Sacha I. Rothschild
CANCERS (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Sebastien Couraud et al.
CLINICAL CANCER RESEARCH (2014)
Guidance for laboratories performing molecular pathology for cancer patients
Ian A. Cree et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
Jean-Yves Douillard et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids
Karen Page et al.
PLOS ONE (2013)
分享论文
